137 related articles for article (PubMed ID: 36774655)
1. 2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.
Chen P; Tang G; Zhu C; Sun J; Wang X; Xiang M; Huang H; Wang W; Li L; Zhang ZM; Gao L; Yao SQ
J Am Chem Soc; 2023 Feb; ():. PubMed ID: 36774655
[TBL] [Abstract][Full Text] [Related]
2. Cell-Active, Reversible, and Irreversible Covalent Inhibitors That Selectively Target the Catalytic Lysine of BCR-ABL Kinase.
Chen P; Sun J; Zhu C; Tang G; Wang W; Xu M; Xiang M; Zhang CJ; Zhang ZM; Gao L; Yao SQ
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202203878. PubMed ID: 35438229
[TBL] [Abstract][Full Text] [Related]
3. Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.
Tang G; Wang W; Wang X; Ding K; Ngan SC; Chen JY; Sze SK; Gao L; Yuan P; Lu X; Yao SQ
Eur J Med Chem; 2023 Nov; 259():115671. PubMed ID: 37499291
[TBL] [Abstract][Full Text] [Related]
4. Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.
Quach D; Tang G; Anantharajan J; Baburajendran N; Poulsen A; Wee JLK; Retna P; Li R; Liu B; Tee DHY; Kwek PZ; Joy JK; Yang WQ; Zhang CJ; Foo K; Keller TH; Yao SQ
Angew Chem Int Ed Engl; 2021 Jul; 60(31):17131-17137. PubMed ID: 34008286
[TBL] [Abstract][Full Text] [Related]
5. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
6. Kinase Inhibition via Small Molecule-Induced Intramolecular Protein Cross-Linking.
Wang X; Sun J; Huang H; Tang G; Chen P; Xiang M; Li L; Zhang ZM; Gao L; Yao SQ
Angew Chem Int Ed Engl; 2024 May; ():e202404195. PubMed ID: 38695161
[TBL] [Abstract][Full Text] [Related]
7. Reversible lysine-targeted probes reveal residence time-based kinase selectivity.
Yang T; Cuesta A; Wan X; Craven GB; Hirakawa B; Khamphavong P; May JR; Kath JC; Lapek JD; Niessen S; Burlingame AL; Carelli JD; Taunton J
Nat Chem Biol; 2022 Sep; 18(9):934-941. PubMed ID: 35590003
[TBL] [Abstract][Full Text] [Related]
8. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
Fournier JCL; Evans JP; Zappacosta F; Thomas DA; Patel VK; White GV; Campos S; Tomkinson NCO
ACS Chem Biol; 2021 Sep; 16(9):1644-1653. PubMed ID: 34397208
[TBL] [Abstract][Full Text] [Related]
9. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
10. Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development.
Tang G; Wang W; Zhu C; Huang H; Chen P; Wang X; Xu M; Sun J; Zhang CJ; Xiao Q; Gao L; Zhang ZM; Yao SQ
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202316394. PubMed ID: 38248139
[TBL] [Abstract][Full Text] [Related]
11. Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues.
Zhao Y; Duan K; Fan Y; Li S; Huang L; Tu Z; Sun H; Cook GM; Yang J; Sun P; Tan Y; Ding K; Li Z
Commun Chem; 2024 Feb; 7(1):31. PubMed ID: 38355988
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents.
Arafet K; Scalvini L; Galvani F; Martí S; Moliner V; Mor M; Lodola A
J Chem Inf Model; 2023 Feb; 63(4):1301-1312. PubMed ID: 36762429
[TBL] [Abstract][Full Text] [Related]
13. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
Das D; Hong J
Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.
Akçay G; Belmonte MA; Aquila B; Chuaqui C; Hird AW; Lamb ML; Rawlins PB; Su N; Tentarelli S; Grimster NP; Su Q
Nat Chem Biol; 2016 Nov; 12(11):931-936. PubMed ID: 27595327
[TBL] [Abstract][Full Text] [Related]
15. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.
Gushwa NN; Kang S; Chen J; Taunton J
J Am Chem Soc; 2012 Dec; 134(50):20214-7. PubMed ID: 23190395
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Targeting Covalent Inhibitors.
Pettinger J; Jones K; Cheeseman MD
Angew Chem Int Ed Engl; 2017 Nov; 56(48):15200-15209. PubMed ID: 28853194
[TBL] [Abstract][Full Text] [Related]
18. Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors.
Francisco KR; Bruystens J; Varricchio C; McCurdy S; Wu J; Lopez-Ramirez MA; Ginsberg M; Caffrey CR; Brancale A; Gingras AR; Hixon MS; Ballatore C
ACS Pharmacol Transl Sci; 2023 Nov; 6(11):1651-1658. PubMed ID: 37974623
[TBL] [Abstract][Full Text] [Related]
19. Versatile Bioconjugation Chemistries of ortho-Boronyl Aryl Ketones and Aldehydes.
Cambray S; Gao J
Acc Chem Res; 2018 Sep; 51(9):2198-2206. PubMed ID: 30110146
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
